Highest-materiality recent filing
TELA Bio shareholders approve 3.5M share equity plan increase, elect three directors
Stockholders approved 3,500,000 share increase to 2019 Equity Incentive Plan; total authorized shares now 10,932,620.
TELA Bio Q1 revenue $19.1M (+3% YoY); net loss $12.3M; reiterates FY2026 revenue growth at least 8%
Revenue $19.1M (+3% YoY), unit growth 13%; European revenue up 41% YoY.
Preliminary Q1 2026 revenue approximately $19.0M; unaudited and subject to change after close.
TELA Bio Q4 2025 revenue $20.9M (+18% YoY); guides FY26 growth at least 8%
Q4 2025 revenue $20.9M (+18% YoY); FY 2025 revenue $80.3M (+16% YoY).
TELA Bio receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified TELA on March 17, 2026 that bid price closed below $1.00 for 30 consecutive business days.
$60M initial loan funded Nov 14, 2025; optional $10M delayed draw. Matures Nov 14, 2030. Interest: 7.85% margin + greater of Reference Rate or 4.25%.
TELA Bio Q3 revenue $20.7M (+9% YoY); upsizes credit facility to $70M with Perceptive
Q3 revenue $20.7M (+9% YoY); net loss $8.6M vs $10.4M year ago; operating loss $7.6M.
TELA Bio appoints William Plovanic to board; expands board to seven members
Board increased from six to seven members; Plovanic appointed as Class I director through 2026 annual meeting.
TELA Bio board changes: Lisa Colleran resigns, Dr. Betty Jo Rocchio appointed
Lisa Colleran resigned from the board on Oct 4, 2025; no disagreement with company.
Revenue $20.2M (+26% YoY); OviTex PRS product revenue up 53% YoY.
TELA Bio appoints Jeffrey Blizard as President; Blizard resigns from Board
Blizard resigned from Board effective June 2, 2025; no disagreement with company.
TELA Bio stockholders approve 3.5M share increase to equity plan and officer liability limitation
Class III directors Blizard, Burgess, O'Brien elected; Burgess received only 9.75M votes for vs 19.54M withheld.
TELA Bio Q1 2025 revenue $18.5M (+12% YoY); net loss $11.3M; reiterates FY revenue guidance $85-88M
Revenue $18.5M, up 12% YoY; OviTex +15%, OviTex PRS +2%.
TELA Bio launches larger OviTex PRS sizes for plastic/reconstructive surgery
Larger sizes include 25x30 cm oval and 25 cm diameter circle, the largest option on the market.
TELA Bio reports Q4 revenue $17.6M (+4% YoY); guides FY2025 revenue $85-88M (+23-27%)
FY2024 revenue $69.3M (+19% YoY); Q4 revenue $17.6M (+4% YoY) missed expectations due to transient disruptions.
TELA Bio Q3 2024: revenue $19.0M (+26% YoY), net loss $10.4M; reaffirms FY2024 guidance
Revenue $19.0M, +26% YoY; OviTex unit sales +39%, OviTex PRS +44% YoY.
TELA Bio prices $37.3M public offering of 12M shares and pre-funded warrants at $2.25/share
Offering consists of 12M shares at $2.25/share and 5.8M pre-funded warrants at $2.2499 each, exercisable at $0.0001.
TELA Bio reports preliminary Q3 revenue of $19M (+26% YoY); implements cost cuts
Revenue $19.0M for Q3 2024 vs $15.1M in Q3 2023, a 26% increase.
TELA Bio Q2 2024 revenue $16.1M (+11% YoY), net loss $12.6M; reiterates FY guidance
Revenue $16.1M, +11% YoY; net loss $12.6M vs $10.8M loss in Q2 2023.
TELA Bio appoints Jeffrey Blizard to Board; stockholders re-elect directors
Jeffrey Blizard, Global Head of Surgical Sales at Abiomed (J&J MedTech), appointed to Board as Class III director, term to 2025 annual meeting.
TELA Bio appoints Greg Firestone as CCO, replaces Peter Murphy terminated without cause
Greg Firestone appointed Chief Commercial Officer effective May 20, 2024; previously Chief Business Officer since October 2017.
TELA Bio Q1 revenue $16.6M (+39% YoY); raises FY2024 guidance to $74.5M-$76.5M
Revenue $16.6M, up 39% YoY; 13th consecutive quarter of ≥35% growth.
TELA Bio launches OviTex IHR for inguinal hernia repair in U.S.
OviTex IHR targets over 665,000 annual U.S. inguinal hernia procedures; three configurations available.
TELA Bio reports record 2023 revenue $58.5M (+41% YoY); guides FY2024 $74-76M
Q4 revenue $17.0M (+46% YoY); full-year revenue $58.5M (+41% YoY).
TELA Bio sells NIVIS distribution rights to MiMedx for at least $8M, up to $12M
Initial $5.0M payment; future payments min $3.0M, max $7.0M based on NIVIS net sales over two years.
TELA Bio Q3 revenue $15.1M (+35% YoY); narrows FY2023 guidance to $57-60M
Revenue of $15.1M, up 35% YoY, marking 11th straight quarter of ≥35% growth.
TELA Bio extends HQ lease to 2030, adds 15,881 sq ft of space
Entered Fourth Amendment to Lease for corporate headquarters in Malvern, PA.
Board member John Nosenzo resigns from TELA Bio board effective Sept 22, 2023
John Nosenzo resigned from TELA Bio's Board of Directors on September 22, 2023.
TELA Bio launches OviTex PRS Long-Term Resorbable for plastic and reconstructive surgery
OviTex PRS Long-Term Resorbable is intended for soft tissue repair or reinforcement in plastic and reconstructive surgery.
TELA Bio Q2 2023 revenue $14.5M (+39% YoY); reaffirms FY23 guidance $60-65M
Q2 revenue $14.5M, up 39% YoY; H1 revenue $26.4M, up 42% YoY.
Lisa Colleran elected with 14,316,642 votes for and 1,055,675 withheld; Doug Evans with 13,535,182 for and 1,837,135 withheld.
TELA Bio Q1 revenue $11.9M (+45% YoY); reaffirms FY2023 guidance $60M-$65M
Revenue $11.9M, up 45% YoY; OviTex revenue +42%, OviTex PRS +52%.
TELA Bio announces public offering of 4.75M shares at $9.50 per share; expects net proceeds ~$42.1M
Offered 4,750,000 shares at $9.50 per share; underwriters have 30-day option for 712,500 additional shares.
TELA Bio preliminary Q1 revenue $11.9M, up 45% YoY; cash $30.1M
Revenue estimated at $11.9M for Q1 2023 vs $8.2M in Q1 2022, a 45% increase.
TELA Bio receives FDA 510(k) clearance for OviTex PRS Long-Term Resorbable
FDA granted 510(k) clearance on March 23, 2023 for OviTex PRS Long-Term Resorbable.
TELA Bio Q4 revenue $11.6M (+39% YoY); FY2023 guidance $60-65M
Full-year 2022 revenue $41.4M (+41% YoY); net loss $44.3M.
TELA Bio launches two larger OviTex LPR configurations for large abdominal hernia repair
New 15x20 cm and 15x25 cm ellipse sizes for ventral and incisional hernias.
Company filed a current report under Item 7.01 to furnish an updated corporate slide deck dated January 10, 2023.
TELA Bio launches NIVIS Fibrillar Collagen Pack for surgical wound management
NIVIS is an absorbent matrix of Type I and Type III bovine collagen for moderately to heavily exudating wounds and minor bleeding.
TELA Bio Q3 revenue $11.2M (+46% YoY); reaffirms FY2022 guidance $42-45M
Q3 revenue $11.2M, up 46% YoY; gross margin 66% vs 60% a year ago.
TELA Bio publishes 24-month BRAVO study showing 2.6% recurrence rate with OviTex in hernia repair
BRAVO study 24-month analysis published in Annals of Medicine and Surgery; 92 patients enrolled.
TELA Bio (TELA) raises ~$34.2M in public offering of 4.6M shares at $8.00
Underwriting agreement with Lake Street Capital Markets for 4M shares at $8.00/share; option for 600K additional shares exercised in full.
TELA Bio furnishes investor slide deck; no specific financial figures in filing
Filing includes a corporate slide deck dated August 15, 2022 for investor meetings.
TELA Bio Q2 revenue $10.4M (+38% YoY); FY2022 guidance $42-45M
Q2 revenue of $10.4M, up 38% YoY; OviTex revenue +22%, OviTex PRS +87%.
TELA Bio stockholders elect all three Class III directors and ratify KPMG as auditor
Vince Burgess, Federica O'Brien, and John Nosenzo elected as Class III directors with >10.7M votes each.
TELA Bio enters $50M credit facility with MidCap; repays $33.2M OrbiMed debt
Borrowed $40.0M upfront from $50.0M term loan facility; unused $10M Tranche 2 conditional on reaching $65M net revenue by FY2023.
TELA Bio Q1 revenue $8.2M (+40% YoY); net loss widens to $10.9M
Revenue grew 40% YoY to $8.2M; OviTex PRS revenue up 111% YoY.
TELA Bio Q4/FY2021 revenue up 48%/62%; guides FY2022 $40-45M; prelim Q1 2022 ~$8M
Q4 2021 revenue $8.4M (+48% YoY); FY2021 revenue $29.5M (+62% YoY).
TELA Bio launches SiteGuard No Rinse Antimicrobial Solution for plastic reconstructive surgery
SiteGuard uses Next Science's XBIO Technology to deconstruct biofilm and provide over 5 hours of protection.
TELA Bio appoints Megan Smeykal as Chief Accounting Officer effective Jan 1, 2022
Megan Smeykal, age 46, promoted from VP – Corporate Controller to Chief Accounting Officer.
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director...
On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the “ Board ”) of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”) and will retire from the Board...
Antony Koblish, the Company’s current President and Chief Executive Officer, will continue in his role as Chief Executive Officer, but as of the Effective Date will no longer hold the title of President.
Jeffrey Blizard, a member of the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”), tendered his resignation from the Board, effective as of June 2, 2025.
the Board appointed Jeffrey Blizard as the new President of the Company, effective as of June 2, 2025
On June 4, 2024, TELA Bio, Inc. (the “ Company ”) appointed Jeffrey Blizard as a member of the Company’s Board of Directors (the “ Board ”).
On September 22, 2023, John Nosenzo, a member of the Board of Directors (the “Board”) of TELA Bio, Inc. (the “Company”), tendered his resignation from the Board, effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event earnings